An assessment of emergent tardive dyskinesia and existing dyskinesia in patients receiving long-acting, injectable risperidone: Results from a long-term study

Schizophrenia Research

Volumn 77, Issue 2-3, 2005, Pages 129-139

  Gharabawi, Georges M ^a   Bossie, Cynthia A ^a   Zhu, Young ^a   Mao, Lian ^a   Lasser, Robert A ^a  

^a Medical Affairs Division   (United States)

Author keywords

Atypical antipsychotic; ESRS; Long acting risperidone; Tardive dyskinesia

Indexed keywords

AMISULPRIDE; ANTIDEPRESSANT AGENT; ANTIPARKINSON AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE; CHLORPROMAZINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; MOOD STABILIZER; PROPRANOLOL; RISPERIDONE; ZUCLOPENTHIXOL DECANOATE;

ADULT; AGED; AGITATION; AKATHISIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEBEPHRENIA; HUMAN; INSOMNIA; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; PARANOID SCHIZOPHRENIA; PARKINSONISM; PHYSICIAN; PRIORITY JOURNAL; RATING SCALE; SCHIZOAFFECTIVE PSYCHOSIS; TARDIVE DYSKINESIA;

ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; ANTIPSYCHOTIC AGENTS; DELAYED-ACTION PREPARATIONS; DYSKINESIA, DRUG-INDUCED; FEMALE; HUMANS; MALE; MIDDLE AGED; PSYCHOTIC DISORDERS; RISPERIDONE; SCHIZOPHRENIA; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; UNITED STATES;

EID: 23444440492     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2005.03.015     Document Type: Article

References (27)

1. C.E. Adams, M.K. Fenton, S. Quraishi, and A.S. David Systematic meta-review of depot antipsychotic drugs for people with schizophrenia Br. J. Psychiatry 179 2001 290 299
2. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders fourth ed. 2000 American Psychiatric Association Washington, DC
3. Y.M. Bai, S.C. Yu, and C.C. Lin Risperidone for severe tardive dyskinesia: a 12-week randomized, double-blind, placebo-controlled study J. Clin. Psychiatry 64 2003 1342 1348
4. C.M. Beasley, M.A. Dellva, R.N. Tamura, H. Morgenstern, W.M. Glazer, K. Ferguson, and G.D. Tollefson Randomised double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol Br. J. Psychiatry 174 1999 23 30
5. J.Y. Chen, Y.M. Bai, L.Y. Pyng, and C.C. Lin Risperidone for tardive dyskinesia Am. J. Psychiatry 158 2001 1931 1932
6. G. Chouinard Effects of risperidone in tardive dyskinesia: an analysis of the Canadian multicenter risperidone study J. Clin. Psychopharmacol. 15 1 Suppl 1 1995 36S 44S
7. G. Chouinard, L. Annable, A. Ross-Chouinard, and J.N. Nestoros Factors related to tardive dyskinesia Am. J. Psychiatry 136 1979 79 82
8. G. Chouinard, A. Ross-Chouinard, L. Annable, and B.D. Jones Extrapyramidal symptom rating scale Can. J. Neurol. Sci. 7 1980 233
9. G. Chouinard, L. Annable, A. Ross-Chouinard, and P. Mercier A 5-year prospective longitudinal study of tardive dyskinesia: factors predicting appearance of new cases J. Clin. Psychopharmacol. 8 4 Suppl 1988 21S 26S
10. C.U. Correll, S. Leucht, and J.M. Kane Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies Am. J. Psychiatry 161 2004 414 425
11. M. Davidson, P.D. Harvey, J. Vervarcke, C.A. Gagiano, J.D. De Hooge, G. Bray, M. Dose, Y. Barak, and M. Haushofer A long-term, multicenter, open-label study of risperidone in elderly patients with psychosis. On behalf of the Risperidone Working Group Int. J. Geriatr. Psychiatry 15 2000 506 514
12. W.W. Fleischhacker, M. Eerdekens, K. Karcher, G. Remington, P.M. Llorca, W. Chrzanowski, S. Martin, and O. Gefvert Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic J. Clin. Psychiatry 64 2003 1250 1257
13. G.M. Gharabawi, C.A. Bossie, R.A. Lasser, I. Turkoz, S. Rodriguez, and G. Chouinard Abnormal Involuntary Movement Scale (AIMS) and Extrapyramidal Symptom Rating Scale (ESRS): cross-scale comparison in assessing tardive dyskinesia Schizophr. Res. 77 2005 119 128
14. W.M. Glazer Extrapyramidal side effects, tardive dyskinesia, and the concept of atypicality J. Clin. Psychiatry 61 Suppl 3 2000 16 21
15. D.V. Jeste, W.M. Glazer, H. Morgenstern, J.A. Pultz, and P.P. Yeung Rarity of tardive dyskinesia with quetiapine treatment of psychotic disorders in the elderly Poster presented at: The 38th Annual Meeting of the American College of Neuropsychopharmacology Acapulco, Mexico, December 12-16 1999
16. D.V. Jeste, J.P. Lacro, A. Bailey, E. Rockwell, M.J. Harris, and M.P. Caligiuri Lower incidence of tardive dyskinesia with risperidone compared with haloperidol in older patients J. Am. Geriatr. Soc. 47 1999 716 719
17. D.V. Jeste, E. Rockwell, M.J. Harris, J.B. Lohr, and J. Lacro Conventional vs. newer antipsychotics in elderly patients Am. J. Geriatr. Psychiatry 7 1999 70 76
18. D.V. Jeste, A. Okamoto, J. Napolitano, J.M. Kane, and R.A. Martinez Low incidence of persistent tardive dyskinesia in elderly patients with dementia treated with risperidone Am. J. Psychiatry 157 2000 1150 1155
19. R. Lasser, C.A. Bossie, G. Gharabawi, M. Eerdekens, and H.A. Nasrallah Efficacy and safety of long-acting risperidone in stable patients with schizoaffective disorder J. Affect. Disord. 83 2004 263 275
20. R.A. Lasser, C.A. Bossie, Y. Zhu, G. Gharabawi, M. Eerdekens, and M. Davidson Efficacy and safety of long-acting risperidone in elderly patients with schizophrenia and schizoaffective disorder Int. J. Geriatr. Psychiatry 19 2004 898 905
21. S.R. Marder Depot neuroleptics: side effects and safety J. Clin. Psychopharmacol. 6 1 Suppl 1986 24S 29S
22. R.L. Rodnitzky Drug-induced movement disorders Clin. Neuropharmacol. 25 2002 142 152
23. N.R. Schooler, and J.M. Kane Research diagnoses for tardive dyskinesia Arch. Gen. Psychiatry 39 1982 486 487
24. K.D. Sethi Movement disorders induced by dopamine blocking agents Semin. Neurol. 21 2001 59 68
25. G.M. Simpson, and J.P. Lindenmayer Extrapyramidal symptoms in patients treated with risperidone J. Clin. Psychopharmacol. 17 1997 194 201
26. Soares, K., Rathbone, J., Deeks, J., 2004. Gamma-aminobutyric acid agonists for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst. Rev. CD000203.
27. G.D. Tollefson, C.M. Beasley Jr., R.N. Tamura, P.V. Tran, and J.H. Potvin Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol Am. J. Psychiatry 154 1997 1248 1254